SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) announced that its Board of Directors is conducting a review of strategic options focusing on maximizing shareholder value. The Company has engaged Cantor Fitzgerald & Co. to act as its strategic and financial advisor for this process.

“We are committed to identifying a strategic plan which will enhance shareholder value while allowing for the acceleration of our development programs, so that our novel immunotherapeutics, GPS and NPS, may benefit cancer patients,” commented Angelos M. Stergiou, M.D., ScD h.c., President and Chief Executive Officer of SELLAS.

Stellas is a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications. The company’s lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which has completed Phase II clinical trials for the treatment of acute myeloid leukemia and malignant pleural mesothelioma; is in Phase II clinical trials to treat multiple myeloma; and is in various development phases as a potential treatment for ovarian cancer. It also develops NeuVax that is in Phase II clinical trials for the treatment of breast cancer; GALE-301 and GALE-302, which have completed early stage trials in ovarian, endometrial, and breast cancers; and GALE-401, an anagrelide controlled release that has completed Phase II clinical trials in patients with essential thrombocythemia, as well as for the treatment of elevated platelets in patients with myeloproliferative neoplasms. The company has strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and Advaxis, Inc. on a research program to evaluate, through a proof of principle trial, a clinical candidate, which comprises the combination of proprietary Lm-based antigen delivery technology and GPS. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

The company’s pipeline included herein for review.

Source: Street Insider

Pin It on Pinterest